Health Condition 1: C541- Malignant neoplasm of endometrium
Conditions
Interventions
None listed
Sponsors
DR RAJKRISHNA B
Eligibility
Inclusion criteria
Inclusion criteria: 1. Histologically confirmed non - metastatic endometrial cancer. 2. Patients staged using both the FIGO 2023 and FIGO 2009 systems. 3. Eastern Co-operative Oncology Group (ECOG) performance score 0-2. 4. Patients who consent to molecular testing.
Exclusion criteria
Exclusion criteria: 1.Patients who have received prior treatment for endometrial cancer. 2.Patients with incomplete clinical or pathological data 3.Uterine sarcoma 4.Prior pelvic radiotherapy, hormonal therapy or chemotherapy 5.Those unfit for chemotherapy and radiation therapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the stage migration in patients with endometrial cancer staged with FIGO 2009 to FIGO 2023 staging system and the outcomes of patients staged with FIGO 2023 staging system.Timepoint: After ethical clearance, 5 years (2 years for patient recruitment, 3 years follow up) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.To evaluate how treatment plans differ based on the FIGO 2023 vs. FIGO 2009 staging 2.To incorporate molecular testing [e.g. MMRd (MSI IHC), POLE, p53] in staging and explore its potential impact on prognosis and treatment. 3. Health related quality of life 4. To evaluate the disease-free survival (DFS) and overall survival (OS) in patients staged with FIGO 2023 staging systemTimepoint: After ethical clearance, 5 years (2 years for patient recruitment, 3 years follow up) | — |
Countries
India
Contacts
Public ContactRAJKRISHNA B
AMALA INSTITUTE OF MEDICAL SCIENCES
Outcome results
None listed